ObjectiveTo investigate the clinical effect of compound lactobacillus combined with mesalazine on moderate active ulcerative colitis and its effect on inflammatory factors levels. MethodsA total of 84 patients with moderate active ulcerative colitis admitted to our hospital from February 2016 to February 2019 were selected as the research subjects and randomly divided into control group and study group, with 42 cases in each group. Patients in the control group were simply administered mesalazine and the study group with compound lactobacillus capsules and mesalazine, for four-week treatment courses. The clinical therapeutic effect, pre- and post-treatment inflammatory factors levels, and the prevalence of adverse reactions were compared and detected between the two groups. ResultsThe total effective rate of patients in the study group (92.86%) was significantly higher than that in the control group (73.81%), and the difference was statistically significant (P＜0.05). After 4 weeks of treatment, both groups yielded significantly decreased levels of serum interleukin 8 (IL-8) and high-sensitivity C-reactive protein (hs-CRP), whereas increased interleukin 4 (IL-4) level. Patients in the study group obtained lower levels of serum IL-8 and hs-CRP, but higher IL-4 level in comparison with the control group, with statistically significant differences (P＜0.05). The incidence of adverse reactions in the study group (11.9%) was lower than that in the control group (7.1%) during the treatment, but the difference was not statistically significant (P＞0.05). ConclusionMesalazine assisted by compound lactobacillus on moderate active ulcerative colitis can significantly improve clinical therapeutic effect and inflammatory factors levels of patients, and thus it is highly safe for treatment and worthy of promotion and application.

无